TurnerTrends Stock Rating Report for ACAD
Data valid for week beginning July 14, 2008
|
ACAD [News]
|
Acadia Pharmaceuticals Inc
|
Company Profile
"ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. Its developing products include Pimavanserin for the treatment of Parkinson's disease psychosis in Phase III trials- Pimavanserin as a co-therapy for schizophrenia in Phase II trials- ACP-104 for the treatment of schizophrenia in Phase IIb clinical trials- Pimavanserin for sleep maintenance insomnia in Phase II trials- AGN-XX and AGN-YY for neuropathic pain in Phase II trials- and AC-262271 for glaucoma in Phase I trials. The company's developing pipeline also consists of ACP-105 for endocrine indications in IND-track development stage- ACP-106 for neuropsychiatry and sleep indications in IND-track development stage- Serotonin program for neuropsychiatry and sleep indications in preclinical stage- pro-cognitive antipsychotic (PCAP) program for schizophrenia in preclinical stage- Muscarinic program for neuropsychiatry and other indications in preclinical stage- and Cannabinoid CB1 program for obesity in preclinical stage. The company has collaboration agreements with Allergan, Inc. to discover, develop, and commercialize new therapeutics for ophthalmic indications, selective muscarinic drugs for the treatment of glaucoma, and new therapeutics for neuropathic pain. ACADIA Pharmaceuticals, formerly known as Receptor Technologies, Inc., was founded in 1993. The company is headquartered in San Diego, California."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Fri, 11 Jul 2008 17:26:37 Etc/GMT | Feuerstein's Biotech-Stock Mailbag: Acadia (at TheStreet.com) | | Tue, 8 Jul 2008 21:41:31 Etc/GMT | Health Winners & Losers: Invitrogen (at TheStreet.com) | | Tue, 8 Jul 2008 19:20:05 Etc/GMT | BofA analyst removes Sell rating on Acadia Pharma (AP) | | Tue, 8 Jul 2008 08:10:30 Etc/GMT | ACADIA Pharmaceuticals upgraded by Banc of America Sec (Briefing.com) | | Wed, 18 Jun 2008 20:17:48 Etc/GMT | 5 Stocks in a Tailspin (at Motley Fool) | | Tue, 17 Jun 2008 19:56:45 Etc/GMT | Health Winners & Losers: Elan (at TheStreet.com) | | Tue, 17 Jun 2008 19:50:41 Etc/GMT | Monday's Worst Stocks in the World (at Motley Fool) | | Tue, 17 Jun 2008 19:15:23 Etc/GMT | Correction: Acadia Pharmaceuticals story (AP) | | Tue, 17 Jun 2008 16:55:41 Etc/GMT | Acadia Gets Halved (at Motley Fool) | | Tue, 17 Jun 2008 14:12:40 Etc/GMT | Premarket roundup: Acadia, Tempur-Pedic (AP) | | Tue, 17 Jun 2008 14:12:04 Etc/GMT | Acadia Primed for Partnering (Zacks.com) | | Tue, 17 Jun 2008 12:50:18 Etc/GMT | Ahead of the Bell: Acadia Pharmaceuticals (AP) | | Mon, 16 Jun 2008 20:40:00 Etc/GMT | Chiquita Brands Int'l, ACADIA Pharmaceuticals: Biggest Price Decliners (CQB, ACAD) (at The Wall Street Journal Online) | | Mon, 16 Jun 2008 20:35:14 Etc/GMT | Small caps close higher (SmallCapInvestor.com) | | Mon, 16 Jun 2008 20:13:50 Etc/GMT | Monday's Winners & Losers: Research In Motion (at TheStreet.com) | | Mon, 16 Jun 2008 19:56:46 Etc/GMT | Health Winners & Losers: Teva (at TheStreet.com) | | Mon, 16 Jun 2008 18:44:34 Etc/GMT | Movers roundup: Acadia, WebMD Health (AP) | | Mon, 16 Jun 2008 17:54:18 Etc/GMT | Russell rises despite surging oil (SmallCapInvestor.com) | | Mon, 16 Jun 2008 15:27:19 Etc/GMT | Acadia shares hit new low on failed study (AP) | | Mon, 16 Jun 2008 15:02:16 Etc/GMT | Acadia Shares Sink on Failed Study (at TheStreet.com) | News provided by Yahoo! Finance |
|
